Nizatidine

axid · nizax · ze-101 · Nizaxi · ZL-101 · Acinon · gastrax · nizaxid

Identifikatoren & physikalische Daten

CAS No.	76963-41-2
Summenformel	C12H21N5O2S2
Durchschnittliche Molmasse	331,5 g/mol
Monoisotopische Masse	331,11366691 g/mol
SMILES	CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
InChIKey	SGXXNSQHWDMGGP-UHFFFAOYSA-N
PubChem CID	4513
ChEMBL	CHEMBL3183075
EC No.	627-310-4
DTXSID	DTXSID5023376

Chemische & physikalische Eigenschaften

XLogP	1,6
Polarare Oberfläche (TPSA)	140
H-Brücken-Donoren	2
H-Brücken-Akzeptoren	8
Frei drehbare Bindungen	9
Schwere Atome	21
Formalladung	0
Komplexität	349
Stoffklassen	Pharmaceutical
Geruch	Mild, sulfur-like odor
Geschmack	Bitter
Color/Form	Crystals from ethanol-ethyl acetateOff-white to buff crystalline solid
Löslichkeit	10-33mg/mLSoluble in waterSparingly soluble in water, soluble in methanol.21.4g/L(temperature not stated)
Human Drugs	Breast FeedingLactationAnti-Ulcer AgentsHistamine H2 AntagonistsGastrointestinal AgentsFDA approved drugs -> Active ingredient
Schmelzpunkt	130-132 °C130-1320C
Collision Cross Section	178.1 Å² [M+Na]+ [CCS Type: DTBuffer gas: N2Ionization: ESI+Dataset: TOXCASTSource Identifier: DTXSID5023376]
Siedepunkt	478.2±45.0 °C(Predicted)
Dichte	1.249±0.06 g/cm3(Predicted)
Lagerbedingungen	Keep in dark place,Inert atmosphere,Room temperature
pKa (Säurekonstante)	2.1, 6.8(at 25℃)
Aggregatzustand	Solid
Farbe	Off-White to Pale Yellow
Merck	14,6660
InChI	InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3
InChIKey	SGXXNSQHWDMGGP-UHFFFAOYSA-N
SMILES	C(NCCSCC1=CSC(CN(C)C)=N1)(NC)=C[N+]([O-])=O
CAS Datenbank	76963-41-2(CAS DataBase Reference)

Sicherheit & Vorschriften

GHS-Einstufung	WarningH302 (97.6%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory.
Weitere Sicherheitsinformationen	IMAP assessments - 1,1-Ethenediamine, N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro-: Environment tier I assessment
FDA-Anforderungen	Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392).
Hazard Classes and Categories	Acute Tox. 4 (97.6%)
Entsorgungsverfahren	SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
Wechselwirkungen	Concurrent use /of antacids/ with histamine H2-receptor antagonists in the treatment of peptic ulcer may be indicated for the relief of painhowever, simultaneous administration of antacids of medium to high potency (80 mmol to 150 mmol HCl) is not recommended since absorption of histamine H2-receptor antagonists may be decreasedpatients should be advised not to take any antacids within 1/2 to 1 hour of histamine H2-receptor antagonists. /Histamine H2-receptor antagonists/Concurrent use /of bone marrow depressants/ with H2-receptor antagonists may increase the risk of neutropenia or other blood dyscrasias. /Histamine H2-receptor antagonists/Histamine H2-receptor antagonists may increase gastrointestinal pHconcurrent administration of ketoconazole with histamine H2-receptor antagonists may result in a marked reduction in absorption of ketoconazolepatients should be advised to take histamine H2-receptor antagonists at least 2 hours after ketoconazole. /Histamine H2-receptor antagonists/Although a decrease in absorption is only reported in the literature for cimetidine and ranitidine, concurrent use with sucralfate may decrease the absorption of any H2-receptor antagonistpatients should be advised to take an H2-receptor antagonist 2 hours before sucralfate. /Histamine H2-receptor antagonists/No drug interactions were reported when nizatidine and theophylline, lidocaine, warfarin, chlordiazepoxide, diazepam, or lorazepam were used together.
Hepatotoxicity	Chronic therapy with nizatidine and other H2 blockers is associated with minor elevations in serum aminotransferase levels in 1% to 4% of patients, but similar rates have been reported in placebo recipients. The ALT elevations are usually asymptomatic and transient and may resolve without dose modification. Rare instances of clinically apparent liver injury have been reported in patients receiving nizatidine, but too few cases have been reported to characterize a typical time to onset or pattern of injury. More information is available on the hepatotoxicity of other H2 blockers such as ranitidine and cimetidine which have been implicated in causing clinically apparent liver injury in 1:20,000 to 1:100,000 users. The time to onset of H2 blocker induced liver injury tends to be short, between 1 and 6 weeks of starting. The typical pattern of serum enzyme elevations varies from hepatocellular to cholestatic, most cases being “mixed”. The injury can be severe, but is typically mild-to- moderate in severity and self-limited in course, resolving within 4 to 12 weeks of stopping. Immunoallergic features (rash, fever, eosinophilia) are uncommon, as is autoantibody formation. Liver biopsy histology often shows centrolobular (zone 3) necrosis with mixed cellular infiltrates and mild cholestasis.
Human Toxicity Excerpts	Nizatidine may inhibit alcohol dehydrogenase in the gastric mucosa and produce higher serum levels of alcohol, but this does not appear to be clinically significant.
Drug Induced Liver Injury	Drug Induced Liver Injury Rank (DILIrank 2.0)NizatidinevLess-DILI-concern5Adverse reactionsDOI:10.1016/j.drudis.2016.02.015
Non-Human Toxicity Excerpts	Studies in rats and mice with oral doses many times the recommended human dose showed no evidence of carcinogenicity.Studies in rats and rabbits with oral doses up to 300 and 55 times the human dose, respectively, have not shown that nizatidine impairs fertility.Rabbits treated with a dose equivalent to 300 times the human dose had abortions, a decreased number of live fetuses, and depressed fetal weights.Nizatidine is distributed into milk in rats, and growth depression has occurred in the offspring of lactating rats treated with the drug.For more Non-Human Toxicity Excerpts (Complete) data for NIZATIDINE (9 total), please visit the HSDB record page.
Effects During Pregnancy and Lactation	◉ Summary of Use during Lactation
USGS Health-Based Screening Levels for Evaluating Water-Quality	NizatidinePharmaceuticalSmith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP
Wassergefährdungsklasse (WGK)	3
Zollcode	29349990
RTECS-Nr.	KM6565000
R-Sätze (R)	22
Toxizität	LD50 in mice, rats (mg/kg): 265, >300 i.v.1685, 1680 orally (Pioch)
Gefahrensymbole	Xn
Sicherheitshinweise (S)	36
Lagerklasse	11 - Combustible Solids
Gefahrstoffdaten	76963-41-2(Hazardous Substances Data)
Gefahrenklasse	Acute Tox. 4 Oral

Anwendungen & Verwendung

Beschreibung

Nizatidine is the fifth H2-antagonist introduced to the world market as an antiulcer agent. It is reported to be effective in the treatment of both duodenal and gastric ulcers or the prevention of their recurrences. Given once-daily, nizatidine’s bioavailability is not diminished by the concurrent administration of an antacid.

Verwenden

Nizatidine is used for treating stomach and duodenum ulcers and other conditions accompanied by elevated acidity of the gastrointestinal tract.